AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more
AbL Diagnostics SA (ABLD) - Total Liabilities
Latest total liabilities as of June 2025: €4.17 Million EUR
Based on the latest financial reports, AbL Diagnostics SA (ABLD) has total liabilities worth €4.17 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
AbL Diagnostics SA - Total Liabilities Trend (2007–2024)
This chart illustrates how AbL Diagnostics SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
AbL Diagnostics SA Competitors by Total Liabilities
The table below lists competitors of AbL Diagnostics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anfield Resources Inc
OTCQB:ANLDF
|
USA | $36.89 Million |
|
AS Trigon Property Development
STU:UG4
|
Germany | €45.44K |
|
NedSense Enterprises NV
AS:NEDSE
|
Netherlands | €417.00K |
|
MAKEMYTRIP (MY1.SG)
STU:MY1
|
Germany | €607.53 Million |
|
Arian Resources Corp.
V:ARC
|
Canada | CA$10.71 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down AbL Diagnostics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbL Diagnostics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbL Diagnostics SA (2007–2024)
The table below shows the annual total liabilities of AbL Diagnostics SA from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €4.32 Million | -46.86% |
| 2023-12-31 | €8.14 Million | -5.99% |
| 2022-12-31 | €8.65 Million | +9081.14% |
| 2021-12-31 | €94.26K | +420.78% |
| 2020-12-31 | €18.10K | -84.70% |
| 2019-12-31 | €118.31K | -80.07% |
| 2018-12-31 | €593.64K | +346.04% |
| 2017-12-31 | €133.09K | -17.93% |
| 2016-12-31 | €162.18K | -79.83% |
| 2015-12-31 | €804.11K | +460.64% |
| 2014-12-31 | €143.43K | -34.43% |
| 2013-12-31 | €218.75K | +151.83% |
| 2012-12-31 | €86.86K | -21.84% |
| 2011-12-31 | €111.14K | +2.38% |
| 2010-12-31 | €108.56K | +90.10% |
| 2009-12-31 | €57.10K | +12.32% |
| 2008-12-31 | €50.84K | -1.20% |
| 2007-12-31 | €51.46K | -- |